Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
|Articles|September 6, 2006
Pharmaceutical Representative Web Seminars
Pharmaceutical Representative is pleased is pleased to bring you informative, interactive, and cost-effective web seminars. These time-saving events are user friendly and designed to deliver information that will improve your bottom line. Please review the list below for upcoming topics.
Advertisement
We are pleased to bring you this informative, interactive, and cost-effective web seminar. This time-saving event is user friendly and designed to deliver information that will improve your bottom line.
Responding Proactively to Customer Questions About Industry Reputationwith Michael C. Pucci,Vice President of External Advocacy, GlaxoSmithKline
Date & Time: New Date Coming Soon!
Duration: 60 minutes
You Will Learn:
- Effective answers to questions about price
- The role of advertising in prevention and better treatment of disease
- How to demonstrate that the pharmaceutical industry cares about patients first
Advertisement
Related to this article
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
The Battle to Own the GLP-1 Patient Journey
4
Novo Announces Drug Discovery Collaboration with Anthropic
5